RA0082

antibody from Oursmab

Targeting: CD276 B7-H3, B7H3, B7RP-2

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0082

Provider

Oursmab

Product name

Enoblituzumab (Biosimilar Reference Antibody) (CD276)

Antibody type

Monoclonal

Description

Enoblituzumab (development code MGA271) is an investigational, humanized Fc-engineered monoclonal IgG1 antibody developed for the treatment of solid tumors. Its design incorporates a modified Fc domain to enhance immune activation. Enoblituzumab functions as a targeted immunotherapeutic agent by binding to a specific antigen highly expressed on a variety of cancer cells. The antibody's primary anti-tumor mechanism is believed to be antibody-dependent cellular cytotoxicity (ADCC), where its optimized Fc region potently engages natural killer (NK) cells and other immune effector cells to kill the bound tumor cells. It may also inhibit pro-tumorigenic signaling pathways within the cancer cell.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Enoblituzumab (Biosimilar Reference Antibody) (CD276)-RA0082-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.